These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 24341895)

  • 1. Structure of the myotonic dystrophy type 2 RNA and designed small molecules that reduce toxicity.
    Childs-Disney JL; Yildirim I; Park H; Lohman JR; Guan L; Tran T; Sarkar P; Schatz GC; Disney MD
    ACS Chem Biol; 2014 Feb; 9(2):538-550. PubMed ID: 24341895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Druglike Small Molecule that Targets r(CCUG) Repeats in Myotonic Dystrophy Type 2 Facilitates Degradation by RNA Quality Control Pathways.
    Wagner-Griffin S; Abe M; Benhamou RI; Angelbello AJ; Vishnu K; Chen JL; Childs-Disney JL; Disney MD
    J Med Chem; 2021 Jun; 64(12):8474-8485. PubMed ID: 34101465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NMR structures of small molecules bound to a model of a CUG RNA repeat expansion.
    Chen JL; Taghavi A; Frank AJ; Fountain MA; Choudhary S; Roy S; Childs-Disney JL; Disney MD
    Bioorg Med Chem Lett; 2024 Oct; 111():129888. PubMed ID: 39002937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myotonic dystrophy type 1 RNA crystal structures reveal heterogeneous 1 × 1 nucleotide UU internal loop conformations.
    Kumar A; Park H; Fang P; Parkesh R; Guo M; Nettles KW; Disney MD
    Biochemistry; 2011 Nov; 50(45):9928-35. PubMed ID: 21988728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure and Dynamics of RNA Repeat Expansions That Cause Huntington's Disease and Myotonic Dystrophy Type 1.
    Chen JL; VanEtten DM; Fountain MA; Yildirim I; Disney MD
    Biochemistry; 2017 Jul; 56(27):3463-3474. PubMed ID: 28617590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NMR spectroscopy and molecular dynamics simulation of r(CCGCUGCGG)₂ reveal a dynamic UU internal loop found in myotonic dystrophy type 1.
    Parkesh R; Fountain M; Disney MD
    Biochemistry; 2011 Feb; 50(5):599-601. PubMed ID: 21204525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Specific Cleavage of an RNA Repeat Expansion with a Dimeric Small Molecule Is Advantageous over Sequence-Specific Recognition by an Oligonucleotide.
    Benhamou RI; Angelbello AJ; Andrews RJ; Wang ET; Moss WN; Disney MD
    ACS Chem Biol; 2020 Feb; 15(2):485-493. PubMed ID: 31927948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of MBNL1-CCUG interaction by small molecules toward potential therapeutic agents for myotonic dystrophy type 2 (DM2).
    Wong CH; Fu Y; Ramisetty SR; Baranger AM; Zimmerman SC
    Nucleic Acids Res; 2011 Nov; 39(20):8881-90. PubMed ID: 21768123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Toxic RNA Catalyzes the Cellular Synthesis of Its Own Inhibitor, Shunting It to Endogenous Decay Pathways.
    Benhamou RI; Angelbello AJ; Wang ET; Disney MD
    Cell Chem Biol; 2020 Feb; 27(2):223-231.e4. PubMed ID: 31981476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive.
    Childs-Disney JL; Hoskins J; Rzuczek SG; Thornton CA; Disney MD
    ACS Chem Biol; 2012 May; 7(5):856-62. PubMed ID: 22332923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlling the specificity of modularly assembled small molecules for RNA via ligand module spacing: targeting the RNAs that cause myotonic muscular dystrophy.
    Lee MM; Childs-Disney JL; Pushechnikov A; French JM; Sobczak K; Thornton CA; Disney MD
    J Am Chem Soc; 2009 Dec; 131(47):17464-72. PubMed ID: 19904940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of flexibility in the rational design of modularly assembled ligands targeting the RNAs that cause the myotonic dystrophies.
    Disney MD; Lee MM; Pushechnikov A; Childs-Disney JL
    Chembiochem; 2010 Feb; 11(3):375-82. PubMed ID: 20058255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules.
    Childs-Disney JL; Stepniak-Konieczna E; Tran T; Yildirim I; Park H; Chen CZ; Hoskins J; Southall N; Marugan JJ; Patnaik S; Zheng W; Austin CP; Schatz GC; Sobczak K; Thornton CA; Disney MD
    Nat Commun; 2013; 4():2044. PubMed ID: 23806903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA Foci, CUGBP1, and ZNF9 are the primary targets of the mutant CUG and CCUG repeats expanded in myotonic dystrophies type 1 and type 2.
    Jones K; Jin B; Iakova P; Huichalaf C; Sarkar P; Schneider-Gold C; Schoser B; Meola G; Shyu AB; Timchenko N; Timchenko L
    Am J Pathol; 2011 Nov; 179(5):2475-89. PubMed ID: 21889481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystallization and preliminary X-ray analysis of RNA oligomers containing CUG repeats which induce type 1 myotonic dystrophy.
    Sato Y; Kimura K; Takénaka A
    Nucleic Acids Symp Ser (Oxf); 2004; (48):117-8. PubMed ID: 17150506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational Investigation of Bending Properties of RNA AUUCU, CCUG, CAG, and CUG Repeat Expansions Associated With Neuromuscular Disorders.
    Taghavi A; Yildirim I
    Front Mol Biosci; 2022; 9():830161. PubMed ID: 35480881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Best practice guidelines and recommendations on the molecular diagnosis of myotonic dystrophy types 1 and 2.
    Kamsteeg EJ; Kress W; Catalli C; Hertz JM; Witsch-Baumgartner M; Buckley MF; van Engelen BG; Schwartz M; Scheffer H
    Eur J Hum Genet; 2012 Dec; 20(12):1203-8. PubMed ID: 22643181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of pharmacophore models for small molecules targeting RNA: Application to the RNA repeat expansion in myotonic dystrophy type 1.
    Angelbello AJ; González ÀL; Rzuczek SG; Disney MD
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5792-5796. PubMed ID: 27839685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudouridine Modification Inhibits Muscleblind-like 1 (MBNL1) Binding to CCUG Repeats and Minimally Structured RNA through Reduced RNA Flexibility.
    deLorimier E; Hinman MN; Copperman J; Datta K; Guenza M; Berglund JA
    J Biol Chem; 2017 Mar; 292(10):4350-4357. PubMed ID: 28130447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of small molecules and oligonucleotides that target a toxic, non-coding RNA.
    Costales MG; Rzuczek SG; Disney MD
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2605-9. PubMed ID: 27117425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.